Page 17 - Joel Perlmutter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1/2 Read More A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s (BIIB.O) Alzheimer’s disease treatment despite the committee’s recommendation against doing so. Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA’s advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel. My rationale was that the FDA needs to re-evaluate how it solicits and uses the advisory committees . because I didn’t think that the firm recommendations from the committee in this case . were appropriately integrated into the decision-making process, Kesselheim said in an email.

Aaron kesselheimDavid knopmanJoel perlmutterThomson reuters trust principlesWashington universityBiogen inc biibo alzheimerSarepta therapeutic incDrug administrationProfessor of medicine at harvard medical schoolBiogen incHarvard medical schoolThomson reuters trustஜோயல் பேர்ல்முத்தேர்தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ப்ரிந்ஸிபல்ஸ்வாஷிங்டன் பல்கலைக்கழகம்ப்ரொஃபெஸர் ஆஃப் மருந்து இல் ஹார்வர்ட் மருத்துவ பள்ளி